The binding and functional properties of a set of six mAb directed against the human gp190 [leukemia inhibitory factor (LIF) receptor] signal transducing molecule were determined. Each of the antibodies reacted with a distinct epitope on gp190 expressed either by gp190-transfected Chinese hamster ovary cells or by the LIF receptor-positive choriocarcinoma JAR cell line. Two of the antibodies (1B4 and 6E6) had binding stoichiometries that were~2-fold lower than those of other mAb (10B2, 12D9 and 7G7), suggesting either that gp190 is present as a pre-associated homodimer in the cell membrane or that part of gp190 is pre-associated with another component. Two mAb (1C7 and 1B4) were found to inhibit LIF binding on the two cell types studied. On JAR cells, this inhibition was, however, restricted to the high-affinity LIF component, suggesting different modes of LIF engagement with the low-and high-affinity receptor species. mAb 1C7 and 1B4 were also found to synergize for inhibiting LIF high-affinity binding. This synergy also extended to the inhibition of LIF-or oncostatin M (OSM)-induced proliferation of a Ba/F3 cell line co-transfected with human gp130 and gp190. However, this mAb combination inhibited LIF-but not OSM-induced haptoglobin secretion by HepG2 cells, suggesting that whereas haptoglobin secretion induced by LIF involves gp130/gp190 common LIF/OSM type I receptors, that induced by OSM mainly involves type II OSM receptors.
Introduction
Leukemia inhibitory factor (LIF) is a cytokine which exerts multiple biological activities on a variety of cellular targets including embryonal stem cells, hepatocytes, adipocytes, neural and glial cells, bone cells, and myoblasts. It is structurally and functionally related to a subset of other cytokines comprising IL-6, IL-11, oncostatin M (OSM), ciliary neurotrophic factor (CNTF) and cardiotrophin-1 (CT-1) (for review see 1,2). All these cytokines have similar tertiary structures containing four amphipathic helices and belong to the long chain subfamily of helical cytokines (3). They have also been shown to have an overlapping spectrum of biological activities. One molecular basis for this functional redundancy relies on the fact that the multi-molecular, high-affinity receptors of Correspondence to: Y. Jacques
Transmitting editor: A. Fischer Received 22 April 1997, accepted 22 July 1997 these cytokines use common signal transducing subunits (4) . One is gp130, initially identified as the IL-6 signal transducer (5) and also designated as the low-affinity receptor for OSM (6) . The other is gp190, identified as the low-affinity receptor for LIF (7) . Homodimerization of gp130 or heterodimerization of gp130 and gp190 have been shown to be key events for signaling mediated by the cytokines of this family. Signal transduction mediated by IL-6 occurs through the formation of a high-affinity IL-6/receptor hexameric complex composed of two molecules of IL-6 associated with two IL-6-specific receptor subunits (low-affinity IL-6R α chain) and two molecules of gp130 (8, 9) . A similar mechanism pertains in the case of IL-11, where formation of a high-affinity signaling complex is brought about by association of the cytokine with a specific low-affinity receptor (IL-11R α chain) and gp130 (10, 11) . In the case of the other hematopoietins of this group, i.e. LIF, OSM, CNTF and CT-1, signaling is initiated through heterodimerization of gp130 with gp190 (6, 12, 13) . A cytokinespecific α chain is also required in the case of CNTF (14) .
Signaling through OSM has also been suggested to occur through additional (type II) receptors involving gp130 and another transducing subunit (OSMRβ) distinct from and homologous to gp190 (15, 16) .
In agreement with its ubiquitous expression during embryonic and adult life, and its involvement in various cytokinedependent pathways, inactivation of the gp130 gene in mouse embryo results in prenatal lethality (17) . Similarly, LIF receptor (gp190)-deficient mice show multiple disorders that result in perinatal death (18) . Accordingly, gp130-and gp190-dependent cytokine systems are involved in a number of pathologies including tumoral, autoimmune and inflammatory diseases. The design of bioreagents able to modulate their function may therefore have therapeutic applications. In addition to the ongoing crystallographic, molecular modeling and mutagenesis studies aiming at elucidating the threedimensional structures of the cytokine-receptor complexes, mAb raised against various structural determinants of cytokines and their receptor subunits will help to dissect the various modes of engagement of the different molecular partners of this family, and provide a first approach to investigate the therapeutical interest of these systems in vivo.
Such antibodies have already been tested at the clinical level in the case of IL-6 (19) and mAb against the human gp130 signal transducer have been obtained which differentially affect the function of gp130 triggering cytokines (20, 21) . In contrast, no mAb against gp190 have been described so far. The present study describes the binding and functional properties of a set of six mAb raised against human gp190.
Methods

Cell lines, antibodies and cytokines
The human choriocarcinoma JAR cell line was obtained from ATCC (Rockville, MD) and cultured in DMEM supplemented with 8% FCS. CHO cells stably transfected with the full-length gp190 cDNA (22) were cultured in RPMI 1640 supplemented with 10% FCS. HepG2 cell line (a kind gift from Dr Christiane Guillouzo, Rennes, France) was cultured in DMEM supplemented with 10% FCS. The anti-human gp190 mAb have been recently raised against a soluble form of the human LIF receptor (gp190) and their initial characterization is described elsewhere (23) . The 9E4 mAb used as control is directed against the TIAR RNA-binding protein (24) . LIF was purified from serum-free conditioned medium of cells transfected with a full-length cDNA encoding for human LIF as described (25) . Recombinant Escherichia coli-derived human OSM and IL-6 were purchased from R&D Systems (Minneapolis, MN). IL-3 was obtained from culture supernatants of WEHI cells.
Radio-iodination of LIF and antibodies
The different anti-gp190 mAb were radiolabeled as described (26) according to a procedure using iodogen as a catalyst (27) . The specific radioactivities obtained were in the range of 1000-2000 c.p.m./fmol. LIF was iodinated according to the chloramine T method described by Tejedor and Ballesta (28) . It was labeled at a sp. act. of~35,000 c.p.m./fmol for highaffinity binding studies and at a sp. act. of~4000 c.p.m./fmol for binding studies under low-affinity conditions.
Binding and cross-competition assays Plastic adherent CHO or JAR cells were incubated with PBS containing 0.05% trypsin and 0.02% EDTA to bring the cells in suspension, washed with FCS containing culture medium and resuspended in PBS containing 0.5% BSA (PBS-BSA). Binding experiments were carried out in PBS-BSA as previously described (25) . Cells (10 6 per well in 96-well roundbottomed plates) were incubated with increased concentrations of labeled LIF or anti-gp190 mAb in a final volume of 50 µl. Non-specific binding was evaluated by including a 100-fold excess of the respective unlabeled cytokine or antibodies. Incubation was carried out under agitation for 90 min (equilibrium conditions) at 4°C. Cell bound (B) and unbound (F) fractions were separated by centrifugation through a layer of dibutyl-phtalat (90%) and paraffin oil (10%). Regression analysis of the binding data was accomplished using a one-or two-site equilibrium binding equation (Grafit; Erithacus Software, Staines, UK).
For competition studies, cells were incubated as described above with a constant and non-saturating concentration of radioactive ligand (with respect to its equilibrium dissociation constant), and increasing concentration of unlabeled competitor ligand, in a final volume of 50 µl. Separation of cell-bound and unbound fractions was carried out as described before. Inhibition curves obtained were analyzed with a fourparameter hyperbolic equation describing competitive inhibition between two ligands for a common binding site (Grafit).
Bioassay with HepG2 cells
HepG2 human hepatoma cells were plated in 96-well flatbottomed plates at a concentration of 5ϫ10 4 cells/well in 200 µl of DMEM containing 10% FCS. After an overnight incubation, cells were washed once with serum-free medium and incubated for 1 h in serum-free medium at 37°C. After a last wash, triplicate wells were treated with serial dilutions of anti-gp190 mAb in 50 µl serum-free medium. After 1 h, 50 µl of DMEM containing dexamethasone (1 µM) and a fixed concentration of LIF (100 pM), OSM (10 pM) or IL-6 (600 pM) was added to each well. After 24 h, the supernatants were harvested and their haptoglobin contents were determined using a symmetric ELISA developed essentially as previously reported (29) . Briefly, purified polyclonal rabbit IgG fraction directed against human haptoglobin (Sigma, St Louis, MO) was coated on 96-well Maxisorb plates (Nunc, Copenhagen, Denmark) overnight at a concentration of 10 µg/ml in PBS. After washing and saturation of the plates with PBS containing 0.5% BSA, the samples were added to the wells at a 1:150 dilution for 3 h at room temperature. The same polyclonal antibody was biotinylated with NHS-biotin (Amersham, Buckinghamshire, UK) and used as a tracer antibody at a final concentration of 0.2 µg/ml. After 3 h of incubation, streptavidin peroxidase (Amersham) was added a 1:16,000 dilution for an additional 1 h. TMB (Medgenix, Fleurus, Belgium) was used as a substrate and the reading was taken at 450 nm. ELISA calibration was performed by using purified haptoglobin (Sigma). The haptoglobin detection limit in the ELISA was 50 pg/ml.
Ba/F3 cell proliferation assay
Ba/F3 cells expressing human gp130 and gp190 have been described elsewhere (30) . Cells were pre-incubated for 30 min at 37°C with various combinations of mAb (1B4, 1C7 or isotype-matched anti-TIAR 9E4), before addition of a subsaturating concentration of IL-3 (2U/ml), LIF (2.6 pM) or OSM (50 pM). After incubation at 37°C for 72 h, cellular proliferation was measured by a MTT-based assay (Sigma) as previously described (31) .
Results
Comparison of LIF and anti-gp190 mAb binding parameters
Six anti-human gp190 mAb were radiolabeled and analyzed for their reactivity with cells expressing receptors for human LIF. Two cell lines were used: a CHO cell line transfected with the human LIF receptor (CHO-190) and the human choriocarcinoma JAR cell line which naturally express it at the cell surface.
Scatchard plots depicting the binding of human LIF and of four anti-gp190 mAb (6E6, 1B4, 10B2 and 7G7) to JAR cells are shown in Fig. 1(A and B) . In agreement with previous studies (25) , these cells express both high-and low-affinity receptors for human LIF. In the experiment reported in Fig Table 1 summarizes the results obtained from several independent experiments and lists the equilibrium binding constants (K d ) and maximal binding capacities (B max ) calculated for LIF and anti-gp190 mAb on JAR cells. When comparing the maximal binding capacities of the mAb, two groups of antibodies could be distinguished. The first group included the 7G7, 10B2 and 12D9 mAb which showed binding capacities in the range of 3000-6000 sites/cell. The second group comprised the 1B4 and 6E6 mAb for which binding capacities were significantly lower than those of the first group (range 1000-2500 sites/ cell). In the case of the 1C7 mAb, specific binding to JAR cells was also observed, which was, however, low and not saturable over the range of labeled mAb concentrations used (up to 20 nM) (not shown). The K d and B max of 1C7 on JAR cells could therefore not be determined with accuracy.
Similar experiments were carried out on the CHO-190 cell line ( Fig. 1C and D, and Table 1 ). In contrast to untransfected CHO cells which express low levels of LIF binding (300-500 low-affinity sites, data not shown), the CHO-human gp190 transfectant expressed~16,000 human LIF binding sites with a K d of 0.36 nM. As already discussed (22) , these pseudohigh-affinity sites likely result from the association of the transfected human gp190 with endogenous hamster gp130 chains and a third, as yet unknown, endogenous CHO com- ponent. As indicated in Fig. 1 (C and D) from the curvature of the LIF Scatchard plot at high LIF concentrations, the beginning of a LIF binding component with much lower affinity could also be detected. This component was repeatedly observed. Their K d and cell density were, however, not possible to determine. As expected, the anti-gp190 mAb did not bind to parental or mock-transfected CHO cells (data not shown). As on JAR cells, they bound to CHO-190 with linear Scatchard plots indicating single-affinity behaviors (Fig. 1C and 1D ). For each mAb, the K d measured on CHO-190 had a value comparable to that measured on JAR cells (Table 1) . Furthermore, a similar rank order in mAb binding stoichiometries was observed: the 7G7, 10B2 and 12D9 mAb displayed the highest binding stoichiometries (range 20,000-40,000 sites/cell), whereas the 1B4 and 6E6 mAb had significantly lower binding capacities (range 14,000-18,000 sites/cell). As on JAR cells also, the 1C7 binding to CHO-gp190 cells was low and not saturable (not shown). Its K d and maximal binding capacity could not be determined with accuracy.
Anti-gp190 mAb cross-competition studies
The anti-gp190 mAb were analyzed for their ability to cross-compete each other for binding. Each mAb was radioiodinated and its binding measured in the presence of increasing concentrations of the other unlabeled mAb. The radiolabeled mAb was used at a concentration lower than its K d in order to avoid saturation effects. Similar data were obtained on the JAR and CHO-190 cell lines, and some of the competition curves are shown in Fig. 2 . For each set of ligands (labeled compound and unlabeled competitor), the maximal extent of inhibition and the concentration of competitor necessary to induce a half maximal inhibitory effect (IC 50 ) were calculated. These parameters are gathered in Table 2 .
As expected, each iodinated mAb is dose-dependently competed out by its respective unlabeled form. The IC 50 s measured are in some cases lower than the corresponding K d of the antibody (compare K d in Table 1 and IC 50 in Table  2 ). For example, the IC 50 of 10B2 is 0.19 nM, whereas the K d of labeled 10B2 is 0.99 nM. These differences indicate that radio-iodination of some mAb results in a significant loss of their affinities. Among the six anti-gp190 mAb, only 12D9 and 10B2 were found to cross-compete each other (Fig. 2C and D, and Table 2 ), suggesting that they might react with a common or close epitopes. However, the binding of 10B2 was completely inhibited by the 1C7 mAb, whereas the binding of 12D9 remained unaffected by 1C7. Therefore 10B2 and 12D9 are not equivalent, and somehow recognize different antigenic structures. Conversely, the fact that the binding of 12D9 is competed out by 10B2 but not by 1C7 indicates that the epitopes recognized by 10B2 and 1C7 are not the same. Partial inhibitory effects were also observed; that of 1B4 on the binding of 10B2, that of 1C7 on the binding of 1B4.
A somewhat surprising observation was the fact that 1B4 markedly enhanced the binding of 1C7. As shown in Fig.  2(F) , a 3-to 4-fold enhancement of 1C7 binding was induced both on JAR and CHO-190 cells. This effect was observed at low concentrations of 1B4 (IC 50 ϭ 0.04 nM), in agreement with the high-affinity binding of 1B4 on both cell lines (Tables  1 and 2 ). Further experiments (not shown) indicated that the main effect of 1B4 was to enhance the binding affinity of 1C7.
Effects of anti-gp190 mAb on LIF binding Some of these effects are shown in Fig. 3 and the complete results are listed in Table 2 . On CHO-190 cells, only the 1C7 mAb was found to completely inhibit LIF binding (Fig. 3B ). This inhibitory effect was obtained at high concentrations of the antibody (IC 50 ϭ 20 nM), a result in agreement with its inability to yield a saturation curve in the direct binding studies (see above Table 1 ). The 1B4 mAb also showed a reproducible inhibitory effect on LIF binding to CHO-190 cells but its effect was only partial (30-40% maximal inhibitory effect). The partial effect of 1B4 was observed at low concentrations (IC 50 ϭ 0.12 nM), reflecting its high binding affinity (K d ϭ 0.33 nM, Table 1 ). The four other mAb did not affect LIF binding (Table 2) .
On JAR cells, the effects of the mAb were investigated both at a low concentration (50 pM) of radiolabeled LIF to investigate preferentially the high-affinity LIF receptor component (Fig. 3A) and at a high concentration (5 nM) of radiolabeled LIF to investigate preferentially the low-affinity LIF receptors (Fig. 3C) . As found on CHO-190 cells, only 1C7 and 1B4 inhibited LIF binding. At high concentrations of LIF, the effect of 1C7 was only very partial and 1B4 had no detectable effect, whereas at low LIF concentrations, 1C7 abrogated most of the LIF binding component and 1B4 had a partial but consistent inhibitory effect representing~30-40% of total LIF binding.
As far as 1B4 was shown to enhance the binding of 1C7 (see above, Fig. 2F ), we analyzed the combination of both antibodies on LIF binding. When working at low LIF concentration (50 pM) (Fig. 3A) , the dose-response curve depicting the inhibitory effect of 1C7 on LIF binding to JAR cells was shifted towards lower mAb concentrations upon including a constant (10 nM) amount of 1B4 in the assay. The IC 50 s characterizing these 1C7 dose-response curves were 100 and 2 nM respectively in the absence and presence of 1B4, therefore demonstrating a strong synergistic effect between the two antibodies. At high LIF concentrations (Fig. 3C) , this synergistic effect did not appear. The partial inhibitory effect of 1C7 was not significantly modified by the presence of 1B4.
In order to analyze more precisely this synergistic interaction, whole LIF binding curves on JAR cells and corresponding Scatchard plots were carried out in the presence of various combinations of 1C7 and 1B4 (Fig. 4) . 1C7 alone at a fixed concentration of 667 nM abrogated most of the LIF high-affinity component on JAR cells, leaving essentially unaffected the low-affinity binding. 1B4 alone at a saturating concentration (10 nM) had a partial inhibitory effect which also specifically affected the high-affinity component. The effect of 1B4 was to partially reduce by~2-fold the affinity of LIF (K d increased from 70 to 130 pM). 1C7 at a low concentration of 10 nM had no detectable effect on LIF binding on JAR cells (not shown). However, when 1C7 (10 nM) was associated with 10 nM of 1B4, the resulting inhibition on high-affinity LIF binding was complete, even stronger than the effect of 1C7 alone at high concentration (667 nM).
Inhibition of LIF induced biological activities
In order to investigate whether the synergy between 1B4 and 1C7 observed on LIF high-affinity binding had a functional correlate, we analyzed their effects on two biological systems: proliferation of a murine Ba/F3 cell line transfected with human gp130 and gp190 (23), and secretion of haptoglobin by hepatoma HepG2 cells (32, 29) . The murine Ba/F3 cell line co-expressing human gp130 and gp190 proliferates in response to IL-3, human LIF or human OSM. As shown in Fig. 5(A) , LIF-induced proliferation was very slightly (10%) inhibited by 1B4 (tested up to 267 nM), whereas it was completely inhibited by 1C7, with an IC 50 of~20 nM. The inhibitory effect of 1C7 was specific since it was not observed on IL-3-driven proliferation (data not shown). When increasing concentrations of 1B4 were combined with a fixed concentration of 1C7 (7 nM), a strong increase of the blocking activity was observed. The enhancing effect of 1B4 was dose dependent with an IC 50 of~3 nM. It was specific since it was not observed with a control mAb (9E4).
Similar results were found when analyzing the effects of anti-gp190 mAb on OSM-induced Ba/F3 cell proliferation (Fig.  5B ). 1B4 had a partial inhibitory effect (~30%), whereas 1C7 had a complete inhibitory effect, with an IC 50 of~5 nM. When adding increasing amount of 1B4 to a fixed concentration of 1C7 (7 nM), an increase of the blocking effect was observed.
On HepG2 cells, LIF raised haptoglobin secretion by~1.8-fold (Fig. 5C ). This induction was slightly inhibited by mAb 1B4 and 10B2 but these inhibitory effects were observed at very high concentrations (Ͼ100 nM) which do not correlate at all with the relative affinities (K d ) of these two mAb (see Table 1 ) or their IC 50 s as determined in the cross-competition experiments (see Table 2 ). Therefore these low inhibitory effects correspond likely to non-specific effects. In contrast, 1C7 induced a complete inhibition of haptoglobin synthesis at concentrations (IC 50 of~250 nM) in agreement with its IC 50 measured on LIF binding (Fig. 3) . When an equimolar mixture of 1B4 and 1C7 was used, a complete inhibition was also observed, but the IC 50 of the mAb equimolar mixture was lowered by~10-fold (~20 nM) as compared to that of 1C7 alone.
As expected, the anti-gp190 mAb or combinations had no effect on IL-6-induced haptoglobin secretion (data not shown). Unexpectedly, however, neither 1C7 nor 1C7 plus 1B4 combination inhibited the secretion of haptoglobin stimulated with OSM (Fig. 5D ).
Discussion
A set of mAb has recently been raised against a soluble form of the human LIF receptor (gp190) (23) . This paper analyses in detail the parameters of interaction of these mAb with different forms of membrane anchored receptors for human LIF and describes some of their functional properties.
A general conclusion which can be drawn from the various cross-competition experiments carried out on the JAR cell line or on the CHO-gp190 cell line is that each of the six mAb studied recognizes a distinct epitope. Other studies analyzing cross-competitions of the mAb on a soluble recombinant form of human gp190 in a sandwich-type ELISA yielded similar conclusions (23) . In these ELISA studies, 10B2 and 12D9 were assigned to the same cluster. In the present report, 10B2 and 12D9 mAb were also found to cross-inhibit each other. However, the differential ability of another mAb (1C7) to interfere with 10B2 but not 12D9 binding indicates that these two mAb react with distinct structures.
On the basis of their binding stoichiometries, two main groups of mAb could be distinguished. The 1B4 and 6E6 mAb displayed stoichiometries which were significantly and 2-fold lower than that measured for 10B2 and 7G7 mAb and, to a lesser extent, for 12D9. Several hypothesis can be proposed to explain these observations. The first, simplest one, is that each gp190 molecule expresses one epitope for the 1B4 and 6E6 mAb, while expressing two equivalent epitopes for each of the 10B2, 7G7 and 12D9 mAb. This hypothesis is, however, unlikely because sandwich-type ELISA assays on a soluble gp190 molecule gave negative results when using any of the anti-gp190 mAb both as capture and tracer mAb, therefore indicating that each mAb has a single binding site per gp190 molecule (23) . A second possibility would be that the cell membrane-associated gp190 molecule exists in two different conformations, one of which is unable to bind the 1B4/6E6 mAb. This could be due, for example, to the association of part of the gp190 subunit with another cell membrane component, thereby masking the epitopes recognized by 1B4 and 6E6. A third hypothesis would assume that gp190 molecules are associated as homodimers in the cell membrane. This homodimerization could induce the localization of the two epitopes for a given mAb (1B4 or 6E6) is such proximity that, due to steric hindrance, only one molecule of mAb can bind. Our binding data cannot decide between these two latter hypothesis. Cross-linking and immunoprecipitation experiments with these novel antigp190 reagents will allow us to investigate the existence of gp190 homodimers or the association of gp190 with other molecular components in the absence of ligand.
Only 1B4 and 1C7 mAb were able to inhibit LIF binding. The effect of 1B4 was only partial and reflected a 2-fold reduction of LIF binding affinity. These antibodies therefore define two separate epitopes on the gp190 molecule involved in the formation of the LIF receptors. Both antibodies were found to exert their inhibitory effects specifically on highaffinity receptors (JAR and CHO cells) leaving the low-affinity component expressed on JAR cells unaffected. From the analysis of cross-linking experiments, the low-affinity LIF receptors on JAR cells have been proposed to involve extra gp190 molecules not combined with gp130 high-affinity converters (22) . If this hypothesis is true, the differential effects of 1B4 and 1C7 on LIF high-and low-affinity binding might indicate a differential binding of LIF by gp190 whether it is associated with gp130 or not. Alternatively and as outlined before, the low-affinity LIF component on JAR cells could correspond to gp190 associated with another cell membrane component which masks the 1B4 and 1C7 epitopes. Finally, the low-affinity LIF receptors on JAR cells might involve a molecular component distinct from the cloned gp190 LIF receptor, an hypothesis which cannot be ruled out at the present time. Immunoprecipitation experiments using antigp190 mAb will again help to decide between these different which is hypothesis.
A synergistic interaction was found between the two inhibitory mAb 1B4 and 1C7. One basis for this synergism was the fact that 1B4 increased the binding affinity of 1C7, both on CHO-190 and JAR cells. This resulted in an increased potency of these mAb combinations to inhibit the binding of LIF as compared to either mAb alone. Again, this synergistic effect was observed specifically on the high-affinity LIF binding component, validating the various hypotheses set out above concerning the nature of the low-affinity LIF binding component on JAR cells.
The effects of anti-gp190 mAb on LIF-dependent biological activities were found to be in good agreement with their binding and cross-competition properties. 1C7 was the only mAb able alone to completely inhibit both LIF-induced cell proliferation of the Ba/F3 cell line co-transfected with gp130 and gp190 as well as LIF-induced haptoglobin secretion by hepatoma HepG2 cells. 1B4 showed low inhibitory effects on these two activities, in agreement with its partial effect on LIF high-affinity binding. Furthermore, the synergism between 1B4 and 1C7 on LIF binding was retained on LIF-dependent biological activities.
Several cytokines in addition to LIF use the gp190 signal transducer in their functional high-affinity receptors (6, 12, 13, 33) . OSM is the best known example. Two highaffinity receptors for OSM have been described, one of which (type I receptor) uses, as does LIF, the gp190 and gp130 signal transducing subunits, whereas the second (type II receptors) uses gp130 in association with another receptor chain (OSMRβ) very recently identified as being homologous to gp190 (15, 16) . Thus type I OSM receptors are proposed to be shared by OSM and LIF, whereas type II receptors are used by OSM but do not bind LIF. These receptors are differentially expressed depending on the type of cell analyzed. The HepG2 cell line has been proposed to express both types of receptors (15, 16) and shown to respond both to LIF and OSM for the secretion of various acute phase proteins (32, 29) . We report here that the synergistic combination of 1B4 and 1C7 mAb completely inhibit LIF-induced haptoglobin secretion by HepG2 cells while having no detectable effect on OSM-induced secretion. This result suggested either that haptoglobin secretion induced by OSM was driven only through the type II receptors or that the two cytokines LIF and OSM were engaging different mode of interaction with gp190 in the common type I receptors. This latter possibility was not unlikely given the fact that isolated gp190 has been described to be a low-affinity receptor for LIF while being unable to bind OSM (34, 35) . Conversely, gp130 is a low-affinity receptor for OSM but does not bind LIF (6, 36, 34) and an anti-gp130 mAb has been described which inhibits OSM biological activity while leaving LIF activity unaffected (29) , suggesting that the two cytokines are also engaging different modes of interaction with gp130. However, our results obtained on the Ba/F3 cell line co-transfected with human gp130 and gp190 argue in favor of the first hypothesis. Indeed, the combination of 1C7 and 1B4 was found to inhibit completely both LIF-and OSM-induced proliferation of this cell line with similar efficiencies, indicating that the epitopes defined by the 1B4 and 1C7 mAb are used in common by LIF and OSM in the gp130/gp190 type I receptor. This observation also implies that LIF and OSM are not using the same receptors to induce haptoglobin secretion in HepG2 cells. Whereas LIF uses a receptor containing gp190 and which is likely the gp130/gp190 common type I LIF/OSM receptor, OSM seems to preferentially use a receptor not containing gp190 and which could be the gp130/OSMRβ type II receptor. The use of anti-gp130 mAb and, when available, anti-OSMRβ chain mAb will help to clarify this observation. It will be also interesting to analyse the effects of 1B4 and 1C7 on the activities of CNTF and CT-1, two cytokines also sharing gp130 and gp190 in their functional receptors.
